Laura Strom, MD

My main clinical interest is in the evaluation, diagnosis and treatment of patients with non-epileptic seizures.

CURRENT RESEARCH SUPPORT 5/28/14-Closed Principal Investigator USL P261-408: An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects with Seizure Clusters Direct cost per patient: $11,698 Length of Study: Until the drug is approved 11/15/2012-Closed Principal Investigator USL P261-402: An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects with Seizure Clusters Direct cost per patient: $9445 Length of study: Until drug is approved 1/02/14-2015 Principal Investigator Marinus 1042-0603: A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults with Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment Direct cost per patient: $9950 Length of study: 9 months 11/19/13-2016 Principal Investigator UCB Biosciences 1379: An Open-Label, Multicenter, Follow-Up Study to evaluate the long-term safety and efficacy of Brivaracetam used as adjunctive treatment in subjects aged 16 years or older with epilepsy Direct Cost per patient: $11,939 7/09/2013-2016 Principal Investigator UCB Biosciences 1358: A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of Brivaracetam in subjects with partial onset seizures Direct Cost per patient: $11,939 1/1/12-Closed Principal Investigator USL P261-401: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects with Seizure Clusters ARTEMIS-1: Acute Rescue Therapy in Epilepsy with Midazolam Intranasal Spray-1 Direct cost per patient: $9445 Length of study: 6 months, dependent upon first seizure cluster after randomization 3/03/11 – 6/27/12 Principal Investigator UCB SP0962 study: An Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated with Long-Term Oral Lacosamide for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects with Idiopathic Generalized Epilepsy Direct costs: $6337 (per patient for entire study) Enrollment: 1 patient Length of study: 56 weeks 7/07/11-2016 Principal Investigator Sunovion BIA-2093-304 study: Efficacy and safety of eslicarbazabine acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in a double-blind, randomized, placebo-controlled parallel-group, multicenter clinical trial Direct costs: $14344 (per patient for entire study) Enrollment: 3 patients Length of study: 41 months 3/03/11 – 01/10/12 Principal Investigator UCB SP0961, An open-label pilot study to assess the safety of oral lacosamide as adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures in subjects with idiopathic generalized epilepsy Direct costs: $7878 (per patient for entire study) Enrollment: 3 patients Length of study: 24 months 11/30/09 – 2016 Principal Investigator Sunovion, 093-050 study; Long-Term Eslicarbazepine Acetate Extension Study Direct costs: $7314 (per patient for entire study) Enrollment: 2 patients at $7314 each = $14,628 Length of study: 36 mos. 12/23/09 – 05/17/12 Principal Investigator Supernus Prosper 302 study: Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR) as Adjunctive Therapy in Subjects with Refractory Partial Epilepsy on up to Three Concomitant Antiepileptic Medications Direct costs: $5270 (per patient for entire study) Indirect costs: $1370 Enrollment: 4 patients at $5270 each = $21,080 Length of study: 14 mos. 12/10/09 – 10/14/11 Principal Investigator Supernus Prosper 301 study: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study to Evaluate the Efficacy and Safety of Oxcarbazepine Extended-Release (OXC XR) (1200 and 2400mg/day) as Adjunctive Therapy in Subjects with Refractory Partial Seizures due to Epilepsy on up to Three Concomitant Antiepileptic Medications Direct costs: $8620 (per patient for entire study) Indirect costs: $2241 Enrollment: 4 patients at $8620 each = $34,480 Length of study: 8-9 mos. 11/06/09 – 08/29/13 Principal Investigator Sunovion 093-045 study: Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs Direct costs: $12030 (per patient for entire study) Indirect costs: $3027 Enrollment: 3 patients at $12030 each = $36,090 Length of study: 2 yrs. 01/31/08 – 01/15/10 Principal Investigator Marinus Pharmaceuticals, Inc, Research 1042-0601 study; an open-label extension study to evaluate the safety, tolerability, and efficacy of ganaxolone as add-on therapy in adult patients with epilepsy consisting of uncontrolled partial-onset seizures. 01/31/08 – 02/25/09 Principal Investigator Marinus Pharmaceuticals, Inc, Research 1042-0600 study; A double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, and efficacy of ganaxolone as add-on therapy in adult subjects with epilepsy consisting of uncontrolled partial-onset seizures.